AnteoTech Ltd (ASX: ADO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AnteoTech Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AnteoTech Ltd (ASX: ADO)
Latest News
Small Cap Shares
Guess which small cap ASX stock is rocketing 42% on Mercedes-Benz deal
Share Gainers
Why Althea, AnteoTech, New Hope, and Omni Bridgeway shares are pushing higher
Industrials Shares
Anteotech share price surges 20% after passing first lithium battery hurdle
Share Gainers
Why these 2 ASX All Ordinaries shares are surging more than 20% today
Healthcare Shares
Why the AnteoTech share price is rocketing 33% today
Healthcare Shares
Here's why the Anteotech (ASX:ADO) share price is leaping 6% today
Healthcare Shares
The AnteoTech (ASX:ADO) share price RAT-tles down 8% following TGA update
Share Fallers
Why AnteoTech, ASX, CIMIC, and Temple & Webster shares are dropping
Healthcare Shares
Rats! How have AnteoTech (ASX:ADO) shares already gained 30% in February?
Coronavirus News
Why are ASX COVID test shares climbing today?
Healthcare Shares
AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues
Healthcare Shares
Why did the AnteoTech (ASX:ADO) share price tumble 13% on Monday
Frequently Asked Questions
-
No, AnteoTech does not pay dividends at this time.
-
AnteoTech Ltd listed on the ASX on 7 April 2000.
ADO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AnteoTech Ltd
AnteoTech Ltd (ASX: ADO) is a biotechnology company that uses its globally patented particle surface management technology to develop specialty products and services. The company's two key fields are end-user diagnostic products and battery technology.
Its Life Sciences division is centred around AnteoBind, a product that connects biological and synthetic surfaces. The technology has various applications and also assists other diagnostic researchers in developing new products and medical devices.
Meantime, the company's Energy division uses AnteoX binding technology to boost the performance of silicon-containing anodes delivering increased capacity, extended cycle life, and superior mechanical properties in lithium-ion batteries.
ADO Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $0.01 | $0.00 | 0.00% | 11,921,668 | $0.01 | $0.01 | $0.01 |
| 05 Feb 2026 | $0.01 | $0.00 | 0.00% | 9,278,730 | $0.01 | $0.01 | $0.01 |
| 04 Feb 2026 | $0.01 | $0.00 | 0.00% | 11,881,932 | $0.01 | $0.01 | $0.01 |
| 03 Feb 2026 | $0.01 | $0.00 | 0.00% | 22,027,574 | $0.01 | $0.02 | $0.01 |
| 02 Feb 2026 | $0.02 | $0.00 | 0.00% | 11,032,327 | $0.02 | $0.02 | $0.01 |
| 30 Jan 2026 | $0.02 | $0.00 | 0.00% | 14,209,285 | $0.02 | $0.02 | $0.02 |
| 29 Jan 2026 | $0.02 | $0.00 | 0.00% | 2,723,774 | $0.02 | $0.02 | $0.02 |
| 28 Jan 2026 | $0.02 | $0.00 | 0.00% | 2,360,990 | $0.02 | $0.02 | $0.02 |
| 27 Jan 2026 | $0.02 | $0.00 | 0.00% | 10,812,818 | $0.02 | $0.02 | $0.02 |
| 21 Jan 2026 | $0.02 | $0.00 | 0.00% | 1,505,054 | $0.02 | $0.02 | $0.02 |
| 20 Jan 2026 | $0.02 | $0.00 | 0.00% | 1,088,079 | $0.02 | $0.02 | $0.02 |
| 19 Jan 2026 | $0.02 | $0.00 | 0.00% | 1,241,726 | $0.02 | $0.02 | $0.02 |
| 16 Jan 2026 | $0.02 | $0.00 | 0.00% | 122,003 | $0.02 | $0.02 | $0.02 |
| 15 Jan 2026 | $0.02 | $0.00 | 0.00% | 2,971,929 | $0.02 | $0.02 | $0.02 |
| 14 Jan 2026 | $0.02 | $0.00 | 0.00% | 1,501,661 | $0.02 | $0.02 | $0.02 |
| 13 Jan 2026 | $0.02 | $0.00 | 0.00% | 938,427 | $0.02 | $0.02 | $0.02 |
| 12 Jan 2026 | $0.02 | $0.00 | 0.00% | 948,939 | $0.02 | $0.02 | $0.02 |
| 09 Jan 2026 | $0.02 | $0.00 | 0.00% | 1,831,581 | $0.02 | $0.02 | $0.02 |
| 08 Jan 2026 | $0.02 | $0.00 | 0.00% | 3,087,895 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Nov 2025 | Geoffrey Cumming | Issued | 5,000,000 | $95,000 |
Issue of options.
|
| 26 Nov 2025 | Geoffrey Cumming | Expiry | 3,500,000 | $66,500 |
Options expired.
|
| 26 Nov 2025 | Glenda McLoughlin | Issued | 7,500,000 | $142,500 |
Issue of options.
|
| 26 Nov 2025 | Glenda McLoughlin | Expiry | 5,000,000 | $95,000 |
Options expired.
|
| 26 Nov 2025 | Merrill Gray | Issued | 30,000,000 | $570,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Geoffrey James Cumming | Non-Executive Director | Apr 2009 |
Dr Cumming has over 20 years of experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and on the Board. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre. He was also Managing Director and CEO of Biosceptre Ltd, an Australian based biotechnology company commercializing a range of products in cancer diagnosis and treatment. During his tenure he was responsible for doing research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. He is the Chair of the Risk Committee.
|
| Ms Glenda McLoughlin | Non-Executive Director | Sep 2021 |
Ms McLoughlin has commercial experience as a senior investment banker, commercial advisor and founder. She has over 20 years of experience on listed company boards. In her executive career she held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Ms McLoughlin has experience in medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. She is a member of the and Risk Committee.
|
| Mr Richard Shubrick Martin | Non-Executive Director | Sep 2005 |
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
|
| Ms Merrill Christina Gray | Non-Executive Director | Jan 2025 |
Ms Gray is an experienced executive and Board member, with a 30-year career spanning a range of critical minerals, renewables and energy businesses. Ms Gray brings experience from the European Union and specifically with German automotive sector with Original Equipment Manufacturers (OEMs) in relation to the management of their battery materials supply chains. Ms Gray has held a range of executive business and technology development roles in Australia and globally. Her executive career has included accessing and developing new markets in Lithium-ion Battery (LiB) cathode and anode materials, LiB recycling, large scale renewable energy generation project development as well as establishing synfuels and waste to energy businesses. During this time, she spent long periods in Germany and worked with Mercedes-Benz, Primobius's first customer, amongst other European OEM's. She is a Member of the Risk Committee.
|
| Mr Scott Waddell | Company SecretaryInterim CFO | Feb 2026 |
-
|
| Scott Waddell | Company SecretaryInterim CFO |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Marcolongo Nominees Pty Ltd | 57,505,701 | 2.10% |
| First Cape Management Pty Ltd | 55,195,509 | 2.00% |
| Addison Lake Quality Hire Pty Limited | 38,844,879 | 1.40% |
| Sisters Palm Beach Pty Ltd | 33,920,000 | 1.20% |
| AWO & CAO Investments Pty Ltd | 31,200,000 | 1.10% |
| Mr Claus Kurt Dzalakowski | 30,000,000 | 1.10% |
| Mr Claus Kurt Dzalakowski & Mrs Michelle Gay Dzalakowski | 27,360,000 | 1.00% |
| Bond Street Custodians Limited | 27,267,749 | 1.00% |
| Mr Peter Frederick Kemmis | 27,040,676 | 1.00% |
| Bond Street Custodians Limited i | 25,100,000 | 0.90% |
| Mr Anthony William Olding & Mrs Caroline Anne Olding | 24,900,000 | 0.90% |
| Bnp Paribas Nominees Pty Ltd | 23,925,035 | 0.90% |
| Marcolongo Nominees Pty Ltd i | 23,356,544 | 0.90% |
| Computer Visions Pty Ltd | 22,132,994 | 0.80% |
| Mcrae Superannuation Pty Ltd | 22,125,000 | 0.80% |
| Terry & Linden Deavin Super Pty Ltd | 21,150,212 | 0.80% |
| Mr Philip Michael Deavin & Mrs Chimene Maree Deavin | 20,162,769 | 0.80% |
| Mr Antonio Di Lalla | 19,986,924 | 0.70% |
| Mr David John Walls | 17,000,000 | 0.60% |
| Mr Richard Shubrick Martin & Mrs Fiona Diana Martin | 16,862,514 | 0.89% |